高级检索
当前位置: 首页 > 详情页

Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Peking Univ, Hosp 3, Dept Pharm, 49 Huayuan North Rd, Beijing 100191, Peoples R China [2]China Japan Friendship Hosp, Pharmaceut Dept, Beijing, Peoples R China [3]Peking Univ, Hosp 3, Dept Haematol, Beijing, Peoples R China [4]Chinese Acad Med Sci, Inst Mat Med, Natl Ctr Pharmaceut Screening, Beijing, Peoples R China [5]Lanzhou Univ, Evidence Based Med Ctr, Lanzhou, Gansu, Peoples R China [6]Lanzhou Univ, Chinese GRADE Ctr, Lanzhou, Gansu, Peoples R China
出处:
ISSN:

关键词: guideline voriconazole individualized medication GRADE

摘要:
Background: Voriconazole (VRZ) is a second-generation triazole antifungal agent with broad-spectrum activity. It is available in both intravenous and oral formulations, and is primarily indicated for treating invasive aspergillosis. The most commonly used dose for adults is 4 mg/kg or 200 mg twice daily. VRZ presents nonlinear pharmacokinetics in adults, whereas drug-drug interactions and cytochrome P450 2C19 (CYP2C19) polymorphism are of great concern for VRZ. Because the liquid chromatography method has been widely used for measuring VRZ blood concentration, and target VRZ blood concentration has been recommended in some guidelines regarding efficacy and safety, therapeutic drug monitoring is considered as a useful tool for VRZ-individualized medication. Also, the CYP2C19 genotype test is available for guiding relevant drugs use in some health care facilities. Our objective was to develop an evidence-based practice guideline for VRZ-individualized medication. Methods: We followed the latest guideline definition from the Institute of Medicine and referred to the World Health Organization handbook for guideline development. The guideline was initially registered in the International Practice Guidelines Registry Platform (IPGRP-2015CN001). The guideline is, in principle, targeted at all Chinese health care providers. The quality of evidence and strength of the recommendations were assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. Results: Twenty-six recommendations were formulated regarding therapeutic drug monitoring, special groups of patients, drug safety, off-indication use, and drug-drug interactions. Of them, 12 were strong recommendations. Most quality of evidence was low, very low, or expert opinions. Conclusions: We developed an evidence-based practice guideline for VRZ-individualized medication, which provided comprehensive and practical recommendations for health care providers. The development of the guideline exposed several research gaps to improve VRZ use.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 医学实验技术 3 区 毒理学 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 3 区 医学实验技术 3 区 毒理学 4 区 药学
JCR分区:
出版当年[2016]版:
Q2 MEDICAL LABORATORY TECHNOLOGY Q3 PHARMACOLOGY & PHARMACY Q3 TOXICOLOGY
最新[2023]版:
Q2 MEDICAL LABORATORY TECHNOLOGY Q2 PHARMACOLOGY & PHARMACY Q2 TOXICOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2016版] 出版当年五年平均[2012-2016] 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者单位: [1]Peking Univ, Hosp 3, Dept Pharm, 49 Huayuan North Rd, Beijing 100191, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)